Medical Laboratories & Research
(GXDX) Genoptix, Inc. – Sales Were up 58% From Last Year
Genoptix, Inc. (GXDX) continues to pressure its 52-week high as shares ride a trend line that began this summer higher. The company’s better than expected third-quarter results, reported on Nov 5, also...
(ARRY) Array BioPharma Sees Positive Results for ARRY-380
Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented...
(GHDX) Genomic Health, Inc Reveals Oncotype DX Data
Genomic Health, Inc. (GHDX) announced that positive results were published in the journal, The Lancet Oncology, from a study of the company’s growth engine, Oncotype DX, in postmenopausal women suffering...
(GHDX) Genomic Health Third Quarter Loss Narrows
Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered...
(DGX) Quest Diagnostics Outperforms – Raises Outlook
Quest Diagnostics’ (DGX) third quarter earnings per share of $1.02 beat the Zacks Consensus Estimate of 96 cents and 86 cents reported in the year ago period. Revenues for the quarter increased 3.9% to $1.9 billion. Clinical testing revenues, which account...
(GHDX) Genomic Health’s Results Reveal Oncotype DX Utility
Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage...
(ARRY) Setback for Array BioPharma’s Drug
Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage trial.
The study...
(GHDX) Good News for Genomic Health
Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health’s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about...
(ARRY) Array Meets Expectations
Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared...
(BRLI) Bio-Reference Laboratories Inc. – In spite of the weak economy, revenue was up 16% from last year
Bio-Reference Laboratories Inc. (BRLI) is posting impressive gains in response to strong revenue growth and expanding margins.
Company Description
Bio-Reference Laboratories, provides clinical laboratory...
(DGX) Quest Diagnostics Incorporated – Growth And Income – Zacks Rank Buy
Quest Diagnostics Incorporated (DGX) recently delivered strong first-quarter results. Earnings per share of 89 cents topped the year-prior 72 cents and exceeded analysts’ expectations by 8.5%.
Company Description
Quest...
(BRLI) Bio-Reference Laboratories – This was the second consecutive quarter that the company has surprised and beat estimates
Bio-Reference Laboratories, Inc. (BRLI) share price has been rallying since the company reported excellent fourth-quarter and full-year results last week. The next-year estimate has held steady, pegged at $1.48 per share, a n 8.5% earnings growth projection.
Company...